Community engagement and clinical trial diversity: Navigating barriers and co-designing solutions—A report from the “Health Equity through Diversity” seminar series
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0281940 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Luiza Reopell und 18 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University College of Medicine, Columbus, OH, United States of America. Hauptthemen laut MEDLINE: Ethnicity, Health Equity. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, Robert Wood Johnson Foundation.
Abstract (Originalsprache)
Introduction
In recent years, there has been increasing awareness of the lack of diversity among clinical trial participants. Equitable representation is key when testing novel therapeutic and non-therapeutic interventions to ensure safety and efficacy across populations. Unfortunately, in the United States (US), racial and ethnic minority populations continue to be underrepresented in clinical trials compared to their White counterparts.
Methods
Two webinars in a four-part series, titled “Health Equity through Diversity,” were held to discuss solutions for advancing health equity through diversifying clinical trials and addressing medical mistrust in communities. Each webinar was 1.5 hours long, beginning with panelist discussions followed by breakout rooms where moderators led discussions related to health equity and scribes recorded each room’s conversations. The diverse groups of panelists included community members, civic representatives, clinician-scientists, and biopharmaceutical representatives. Scribe notes from discussions were collected and thematically analyzed to uncover the central themes.
Results
The first two webinars were attended by 242 and 205 individuals, respectively. The attendees represented 25 US states, four countries outside the US, and shared various backgrounds including community members, clinician/researchers, government organizations, biotechnology/biopharmaceutical professionals, and others. Barriers to clinical trial participation are broadly grouped into the themes of access, awareness, discrimination and racism, and workforce diversity. Participants noted that innovative, community-engaged, co-designed solutions are essential.
Conclusions
Despite racial and ethnic minority groups making up nearly half of the US population, underrepresentation in clinical trials remains a critical challenge. The community engaged co-developed solutions detailed in this report to address access, awareness, discrimination and racism, and workforce diversity are critical to advancing clinical trial diversity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The Ohio State University College of Medicine, Columbus, OH, United States of America.
- The Ohio State University College of Nursing, Columbus, OH, United States of America.
- The Ohio State University James Center for Cancer Health Equity, Columbus, OH, United States of America.
- Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN, United States of America.
- The University of North Carolina at Chapel Hill School of Nursing, Chapel Hill, NC, United States of America.
- Genentech Inc., San Francisco, CA, United States of America.
ORCID-Profile: Luiza Reopell, Timiya S Nolan, Ashley Leak Bryant, Clarence Jones, Jeff Grever, Adam Soliman, Daniel M Walker, Faith Metlock, Joshua J Joseph
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Robert Wood Johnson Foundation
- Genentech
- Pfizer
- Ohio State University
Zitieren
APA
Reopell, L., Nolan, T. S., Gray, D. M., Williams, A., Brewer, L. C., Bryant, A. L., Wilson, G., Williams, E., Jones, C., McKoy, A., Grever, J., Soliman, A., Baez, J., Nawaz, S., Walker, D. M., Metlock, F., Zappe, L., Gregory, J., & Joseph, J. J. (2023). Community engagement and clinical trial diversity: Navigating barriers and co-designing solutions—A report from the “Health Equity through Diversity” seminar series. PLOS ONE. https://doi.org/10.1371/journal.pone.0281940
Vancouver
Reopell L, Nolan TS, Gray DM, Williams A, Brewer LC, Bryant AL, et al. Community engagement and clinical trial diversity: Navigating barriers and co-designing solutions—A report from the “Health Equity through Diversity” seminar series. PLOS ONE. 2023. doi:10.1371/journal.pone.0281940
BibTeX
@article{Reopell2023,
author = {Reopell, Luiza and Nolan, Timiya S and Gray, Darrell M and Williams, Amaris and Brewer, LaPrincess C and Bryant, Ashley Leak and Wilson, Gerren and Williams, Emily and Jones, Clarence and McKoy, Alicia and Grever, Jeff and Soliman, Adam and Baez, Jna and Nawaz, Saira and Walker, Daniel M and Metlock, Faith and Zappe, Lauren and Gregory, John and Joseph, Joshua J},
title = {Community engagement and clinical trial diversity: Navigating barriers and co-designing solutions—A report from the “Health Equity through Diversity” seminar series},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0281940}
}
EUVIMED